Study of a new drug for cancers expressing CD44v6
Part of Cancer, Lungs & breathing, Women’s health & pregnancy clinical trials.
This trial tests a new radioactive drug called [177Lu]Lu-AKIR001 for patients with certain advanced cancers (like thyroid, head and neck, lung, vulvar, or cervical cancer) that have a specific protein called CD44v6 on their surface. The goal is to see if this treatment can help when standard options have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- 18 years or older
- Have one of these cancers that has spread and cannot be removed: anaplastic, poorly differentiated or radioiodine-refractory thyroid cancer; head and neck squamous cell cancer; non-small cell lung cancer; vulvar squamous cell cancer; or cervical squamous cell cancer
- Your cancer has gotten worse despite trying available standard treatments
- You must be in fairly good health (able to do daily activities) and have adequate organ function
- You agree to use effective contraception if you could become pregnant or get someone pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if an existing drug (used for other conditions) can help people with advanced thyroid cancer who have run out of treatment options. You'll get a new drug and be monitored to see if it shrinks your cancer or slows it down.
This trial tests a new radioactive drug (177Lu-BL-ARC001) for people with advanced lung, breast, head and neck, or other solid tumors that have not responded to standard treatments. It aims to see if the drug can target and shrink tumors while limiting side effects.
This trial tests a radioactive drug called 177Lu-LNC1004 for people with a type of thyroid cancer that is no longer responding to standard treatments. The drug targets a protein called FAP found on tumor cells, which may help shrink tumors and slow disease progression.
This trial tests a new radioactive drug (Lutetium-177 BL-ARC001) for people with advanced solid tumors, including stomach, bowel, and other cancers. It aims to see if the treatment is safe and how well it works.
This trial tests a new radioactive drug called [177Lu]Lu-DFC413 for people with certain advanced solid tumors that have stopped responding to standard treatments. The drug is designed to target cancer cells with a specific marker seen on a special scan.
This early-phase study tests two radioactive medicines that first help doctors see tumors and, in some parts of the study, treat them. It may help people with advanced, hard-to-remove cancers that have a specific tumor marker (CA IX).
Hear when a new Poorly Differentiated Thyroid Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.